The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of esketamine within its marketing authorisation for treating major depressive disorder in adults at imminent risk for suicide.
For information, the company have requested additional time to provide an evidence submission to NICE and therefore the timelines for this appraisal are currently to be confirmed.
NICE will continue to monitor the situation and provide an update as and when the situation changes.